ABBV - AbbVie Inc.

NYSE - NYSE Delayed Price. Currency in USD
91.87
+0.51 (+0.56%)
At close: 4:00PM EDT

92.50 +0.63 (0.69%)
After hours: 4:28PM EDT

Stock chart is not supported by your current browser
Previous Close91.36
Open90.96
Bid92.20 x 100
Ask92.50 x 300
Day's Range90.52 - 92.28
52 Week Range64.61 - 125.86
Volume5,106,644
Avg. Volume7,729,304
Market Cap145.769B
Beta1.64
PE Ratio (TTM)27.84
EPS (TTM)3.30
Earnings DateApr 26, 2018
Forward Dividend & Yield3.84 (4.20%)
Ex-Dividend Date2018-04-12
1y Target Est119.52
Trade prices are not sourced from all markets
  • Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX
    Zacks6 hours ago

    Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX

    Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.

  • PR Newswire8 hours ago

    AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

    - In clinical studies, more than half of patients receiving risankizumab achieved complete skin clearance (PASI 100) at one year (52 weeks) (1) - The Biologics License Application is supported by four ...

  • A Look at Biogen’s Performance in 1Q18
    Market Realist8 hours ago

    A Look at Biogen’s Performance in 1Q18

    In 1Q18, Biogen (BIIB) generated revenues of $3.1 billion compared to $2.8 billion in 1Q17. That was an ~11% growth on a year-over-year (or YoY) basis and a ~5% decline on a quarter-over-quarter basis.

  • PR Newswire8 hours ago

    AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients

    - In SELECT-SUNRISE, upadacitinib met the primary endpoint of ACR20 across all doses (7.5 mg, 15 mg, 30 mg, once-daily) at week 12, with a significant difference in ACR20 compared to placebo observed as ...

  • Why Incyte Stock Fell ~9% on April 24
    Market Realist9 hours ago

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) saw a steep decline in its stock price. It registered a decline of ~5% during pre-market trading. The stock price decline was triggered by the news regarding Incyte-Eli Lily (LLY) drug Baricitinib, which is under FDA (U.S. Food and Drug Administration) review.

  • Gilead Sciences’ Inflammation Research Is Seeing Rapid Progress
    Market Realist9 hours ago

    Gilead Sciences’ Inflammation Research Is Seeing Rapid Progress

    Gilead Sciences (GILD) is currently studying an investigational therapy, filgotinib, in five Phase 3 trials as a treatment option for RA (rheumatoid arthritis), ulcerative colitis, and Crohn’s disease. The company is studying this therapy for RA in its FINCH 1, 2, and 3 trials. While the FINCH 2 study has completed enrolment, FINCH 1 and FINCH 3 are expected to complete enrolment in 2Q18 and 3Q18, respectively.

  • Reuters19 hours ago

    Supreme Court upholds legality of patent review process

    The U.S. Supreme Court on Tuesday gave its stamp of approval to a government review process prized by high technology companies as an easy and cheap way to combat "patent trolls" and others that bring patent infringement lawsuits. The justices ruled 7-2 that a type of in-house patent review at the U.S. Patent and Trademark Office does not violate a defendant's right under the U.S. Constitution to have a case adjudicated by a federal court and jury. The court ruled against Oil States International Inc (OIS.N), a Houston-based oilfield services company that had challenged the legality of the process, called inter partes review (IPR).

  • Gilead Sciences Focuses on Its Liver Disease Portfolio
    Market Realistyesterday

    Gilead Sciences Focuses on Its Liver Disease Portfolio

    By mid-2018, Gilead Sciences (GILD) expects its share of the HCV (hepatitis C) market, where it competes with AbbVie (ABBV), Merck (MRK), and Bristol-Myers Squibb (BMY), to stabilize. This stabilization is anticipated despite rapidly declining drug prices and reducing treatment duration due to new and better therapies. While the company is not expecting any disruptive product launches in the HCV segment in the next few years, it expects gradually declining patient numbers to affect revenue. Liver disease research programs

  • Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?
    Zacksyesterday

    Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?

    Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.

  • Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down
    Zacksyesterday

    Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down

    Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.

  • Investopediayesterday

    How Does Biogen Make its Money?

    Biogen is a healthy biotechnology company producing a stream of illness-fighting drugs. Its big sellers treat MS, and it is diversifying its product line.

  • Reutersyesterday

    U.S. Supreme Court upholds legality of patent review process

    The U.S. Supreme Court on Tuesday gave its stamp of approval to a government review process prized by high technology companies as an easy and cheap way to combat "patent trolls" and others that bring patent infringement lawsuits. The justices ruled 7-2 that a type of in-house patent review at the U.S. Patent and Trademark Office does not violate a defendant's right under the U.S. Constitution to have a case adjudicated by a federal court and jury. The court ruled against Oil States International Inc, a Houston-based oilfield services company that had challenged the legality of the process, called inter partes review (IPR).

  • This Small Biotech Is Building on a Surprising Success
    Motley Foolyesterday

    This Small Biotech Is Building on a Surprising Success

    Enanta Pharmaceuticals helped AbbVie score big last year. Now it's setting its sights even higher.

  • Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma
    Motley Foolyesterday

    Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma

    It's a lot easier to be patient once those quarterly payments start adding up.

  • Reutersyesterday

    Amid drug price worries, earnings to test U.S. pharma, biotech shares

    Major U.S. pharmaceutical and biotechnology companies, whose shares have been laggards even in a sluggish market, face a litmus test in the corporate earnings season as investors already gun-shy over concerns about pressures on drug prices prepare to give a sharp eye for both hits and misses. As a group, pharmaceutical stocks in the S&P 500 are down about 4 percent so far this year, while S&P biotech stocks are off about 6 percent. Shares of Biogen Inc, Celgene Corp and Bristol-Myers Squibb Co are all down at least 14 percent this year.

  • Johnson & Johnson’s Revenues Continued to Rise in 1Q18
    Market Realist2 days ago

    Johnson & Johnson’s Revenues Continued to Rise in 1Q18

    Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.

  • Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy
    Zacks2 days ago

    Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy

    Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.

  • AbbVie And Other Great Pharma And Biotech Income Stocks
    Simply Wall St.5 days ago

    AbbVie And Other Great Pharma And Biotech Income Stocks

    Pharmaceutical and biotech stocks are rarely seen as effective dividend stocks. Although drugs are also relatively non-cyclical these stocks are often impacted by ever-changing regulatory environment and the strength ofRead More...

  • Mylan NV Could Be Closer to a Breakout Than Most Traders Realize
    InvestorPlace6 days ago

    Mylan NV Could Be Closer to a Breakout Than Most Traders Realize

    If it seems like Mylan NV (NASDAQ:MYL) has gotten far more media attention of late than it usually does — almost all of it bullish — you’re not crazy. The recent investor-day event helped the company toot its own horn to be sure, still, MYL stock has been strangely stuck in neutral in recent days. It’s a curious situation that defies the news Mylan has been dishing out that’s been turning some heads.

  • Gilead Sciences Expects Decline in Earnings in Fiscal 2018
    Market Realist6 days ago

    Gilead Sciences Expects Decline in Earnings in Fiscal 2018

    Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.

  • Moody's6 days ago

    Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising

    The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.

  • Roche Hemophilia Drug Gets Breakthrough Therapy Designation
    Zacks7 days ago

    Roche Hemophilia Drug Gets Breakthrough Therapy Designation

    The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.

  • Gilead Sciences May Witness Significant Drop in Revenues in 2018
    Market Realist7 days ago

    Gilead Sciences May Witness Significant Drop in Revenues in 2018

    Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...

  • What Analysts Recommend for Gilead Sciences in April 2018
    Market Realist7 days ago

    What Analysts Recommend for Gilead Sciences in April 2018

    In 4Q17, Gilead Sciences (GILD) reported revenues close to $5.9 billion, which is a year-over-year (or YoY) drop of around 19%. Gilead Sciences reported net product sales close to $5.8 billion in 4Q17, which is a YoY decline of 19% and a quarter-over-quarter drop close to 9%. The company also reported net product sales close to $25.7 billion for fiscal 2017, which is a YoY decline of around 14%.

  • Analysts’ Recommendations for AbbVie in April 2018
    Market Realist7 days ago

    Analysts’ Recommendations for AbbVie in April 2018

    In April 2018, the FDA notified AbbVie (ABBV) and Neurocrine Biosciences that it would need more time to review liver function test data provided by AbbVie with its new drug application for Elagolix for the management of endometriosis-associated pain, extending its Prescription Drug User Fee Act goal date by three months to 3Q18. In 4Q17, the FDA granted Elagolix priority review. In clinical trials, Elagolix was evaluated for safety and efficacy in ~1,700 women with moderate-to-severe endometriosis-related pain.